07:00 , Aug 27, 2007 |  BC Week In Review  |  Clinical News

BC-7013: Phase I started

Nabriva began a Phase I trial of topical BC-7013. Nabriva Therapeutics Forschungs GmbH , Vienna, Austria   Product: BC-7013   Business: Infectious   Molecular target: NA   Description: Pleuromutilin antibiotic agent   Indication: Treat bacterial...